All ExchangesCASI Pharmaceuticals Stock Forecast
CASI Pharmaceuticals stock price ended on $2.04 on Wednesday after losing 0.97%
(Updated on Sep 20, 2023)
The CASI Pharmaceuticals stock price fell by -0.97% on the last day (Wednesday, 20th Sep 2023) from $2.06 to $2.04. During the last trading day the stock fluctuated 3.94% from a day low at $2.03 to a day high of $2.11. The price has fallen in 6 of the last 10 days and is down by -5.87% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -13 thousand shares and in total, 9 thousand shares were bought and sold for approximately $19.19 thousand.
Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.
The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -21.47% during the next 3 months and, with a 90% probability hold a price between $1.51 and $1.81 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
CASI Signals & Forecast
There are few to no technical positive signals at the moment. The CASI Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.10 and $2.27. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, August 24, 2023, and so far it has fallen -18.07%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.
Support, Risk & Stop-loss for CASI Pharmaceuticals stock
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0799 between high and low, or 3.94%. For the last week the stock has had daily average volatility of 2.08%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (CASI) For The Upcoming Trading Day Of Thursday 21st
For the upcoming trading day on Thursday, 21st we expect CASI Pharmaceuticals to open at $2.06, and during the day (based on 14 day Average True Range), to move between $1.93 and $2.15, which gives a possible trading interval of +/-$0.107 (+/-5.23%) up or down from last closing price. If CASI Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 10.46% move between the lowest and the highest trading price during the day.
With no support below and resistance from accumulated volume @ $2.30, some $0.260 (12.75%) from the current price of $2.04, our system finds the risk reward not very attractive.
Is CASI Pharmaceuticals stock A Buy?
CASI Pharmaceuticals holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Current score: -5.148 Open Broker Account
Strong Sell Candidate UnchangedPredicted Opening Price for CASI Pharmaceuticals of Thursday, September 21, 2023
The predicted opening price is based on yesterday's movements between high, low, and closing price.
| Fair opening price September 21, 2023 | Current price |
|---|---|
| $2.06 | $2.04 (Undervalued) |
Remember To Visit Our YouTube Channel
Trading levels for CASI
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 2.14 | 4.90 % | |
| R2 | 2.11 | 3.40 % | ||
| R1 | 2.09 | 2.47 % | ||
| Current price: | 2.04 | |||
| Support | S1 | 2.03 | -0.517 % | |
| S2 | 2.01 | -1.44 % | ||
| S3 | 1.98 | -2.94 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 2.51 | 23.04 % | |
| R2 | 2.50 | 22.55 % | ||
| R1 | 2.30 | 12.75 % | ||
| Current price | 2.04 | |||
| Support | S1 | 0 | . | |
| S2 | 0 | . | ||
| S3 | 0 | . |
FAQ
Click here for our free guide on how to buy CASI Pharmaceuticals Stock.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T inve... CASI Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
